Background: Severity of rheumatoid arthritis and progression of radiographic joint damage have decreased over the last decades.
Aim: To examine whether this trend is attributable to an underlying trend towards milder disease or to improved treatment.
Methods: The study used an inception cohort of patients with early rheumatoid arthritis seen at the Wichita Arthritis Center, Wichita, Kansas, USA, since 1973 and monitored prospectively since their first clinic visit through clinical, radiographic, laboratory, demographic and self-reported data. The radiographic disease progression in patients with disease onset in the 1970s, 1980s and 1990s was compared using a multivariate regression model for longitudinal data. The analysis was adjusted for differences in baseline predictors, type of disease-modifying antirheumatic drugs (DMARDs) and steroid use.
Results: 418 patients with rheumatoid arthritis with radiographic follow-up were included. Patients in earlier decades used fewer DMARDs, had longer disease durations and higher tender joint counts at their first visit. Other important predictors of disease progression did not differ significantly between decades of disease onset. The unadjusted rates of radiographic progression differed between decades (analysis of variance, p = 0.01), with a significant trend towards less radiographic progression in more recent times (trend, p<0.001). However, after adjusting for DMARD use, steroid use and baseline predictors, differences between decades vanished (analysis of variance, p = 0.40) and the trend towards less radiographic progression disappeared (trend, p = 0.45).
Conclusion: These results suggest that the observed trend towards milder disease in rheumatoid arthritis is attributable to more effective antirheumatic treatment and not to a secular trend.
- ANOVA, analysis of variance
- DMARD, disease-modifying antirheumatic drug
- ESR, erythrocyte sedimentation rate
- HAQ, Health Assessment Questionnaire
- MTX, methotrexate
Statistics from Altmetric.com
Published Online First 15 March 2006
Funding: AF is supported by the Centocor Health Outcomes in Rheumatic Diseases (CHORD) fellowship and the Kirkland Scholars Fellowship.
Competing interests: None declared.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.